Dr. Grandori is the CEO of SEngine Precision Medicine, a company specializing in personalized cancer treatment options using organoid technology. SEngine's approach tests over 200 cancer drugs against a patient's tumor organoid outside the body, offering insights that DNA sequencing alone can't provide. Dr. Grandori's background in cancer molecular biology and her role in pioneering research on the undruggable MYC oncogene have positioned her as a leader in the field. Since 2015, she has led SEngine Precision Medicine in its mission to empower patients and oncologists with informed treatment choices.